The Pipeline

Melbourne, Australia, 10 June 2026 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is pleased to announce the issuance of a patent for “Genetically modified cells and uses thereof” by the Japanese Patent Office.

This is the second granted patent in Japan […]

By Drs Ian Nisbet & Walid Azar

As published in Pharmaphorum – 14 May 2026

Immune cell therapies have transformed the treatment of certain blood cancers over the past decade. However, when it comes to solid tumours, perceptions about their effectiveness often lag behind the emerging scientific evidence.

In particular, Chimeric Antigen Receptor – Natural Killer (CAR-NK) […]

April 9 (US ET), 2026 – Melbourne, Australia, and Tampa, FL – Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women’s diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership.

The companies […]

Melbourne, Australia, 29 January 2026 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is pleased to announce the granting of a second patent in China for “Genetically modified cells and uses thereof” by the Chinese Patent Office.

This patent extends the Company’s […]

Cartherics is proud to announce the successful certification of our new clean room facility, marking a significant milestone in our journey toward delivering off-the-shelf cell therapies for cancer and endometriosis. 

This milestone builds on the recent unveiling of our cleanroom facility, as announced here, and reflects our continued progress in […]

Melbourne, Australia, 11 September 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, is proud to announce that it has been named ‘Most Promising iPSC Therapy Pipeline in APAC’ in the Asia Pacific Cell […]

Melbourne, Australia, 27 August 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseases, with lead programs in ovarian cancer and endometriosis, today announced the granting of a patent for ‘Method for Providing Immune Cells with Enhanced Function’ by the Chinese Patent Office.

This […]

Cartherics is delighted to be featured in the June 2025 issue of Pharma Technology Focus, drawing attention to our innovative approach to cell therapy. Unlike traditional cell therapies, Cartherics employs gene-edited natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) from umbilical cord blood.

This approach aims to enhance the immune system’s […]